Investors in Bausch Health Companies Inc. (BHC) need to pay close attention to the stock based on moves in the options market lately. That is because the April 17, 2026 $15 Call had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It ...

It has been about a month since the last earnings report for Bausch Health (BHC) . Shares have lost about 15.2% in that time frame, underperforming the S&P 500.But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Bausch due for a breakout? Well, first let's take a quick look at its most recent earnings report in order to get a better handle on the recent catalysts for Bausch Health Cos Inc. before we dive into how investors and analysts h ...

Group 1 - The U.S. Supreme Court recently overturned the Trump administration's tariff policy, prompting numerous companies to sue for full refunds of tariffs paid [1] - FedEx is the first major U.S. company to initiate legal action, seeking a full refund of tariffs, which could lead to a $1 billion reduction in adjusted operating profit for the current fiscal year [1] - Over 1,400 importers have already filed lawsuits against the Trump administration regarding tariffs, with expectations that more companies will join the legal actions [1] Group 2 - The U.S. government is considering raising the global tariff baseline to 15% and is planning to impose new tariffs on six industries, including large batteries and industrial chemicals [2] - The process for companies to reclaim paid tariffs is expected to be lengthy, and new tariff measures may hinder consumer hopes for lower prices [2] - Even if companies recover paid tariffs, it may only offset a portion of the losses incurred over the past year due to tariffs, leading to no immediate plans for price reductions [2]

Core Viewpoint - Ironwood Pharmaceuticals (IRWD) and Bausch Health (BHC) are both active in the branded gastrointestinal (GI) drug market, focusing on treatments for irritable bowel syndrome (IBS) and other therapeutic areas. Ironwood is a smaller, focused company centered around its key GI drug, while Bausch Health is a larger, diversified drugmaker with a broader product range [1][2]. Group 1: Ironwood Pharmaceuticals (IRWD) - Ironwood's primary product, Linzess (linaclotide), is approved for treating IBS with constipation (IBS-C) and functional constipation, marketed in collaboration with AbbVie (ABBV) [3][4]. - In the first nine months of 2025, Ironwood's share of net profit from Linzess sales in the U.S. was $244.1 million, with sales increasing due to strong demand [5]. - Ironwood anticipates total revenues of $450-$475 million in 2026, representing a 54% year-over-year increase at the midpoint [6]. - The company is developing apraglutide, a next-generation GLP-2 analog for short bowel syndrome with intestinal failure, with a confirmatory study expected to start in the first half of 2026 [7]. - Despite the positive outlook for Linzess and apraglutide, Ironwood's heavy reliance on a single product raises concerns [8]. Group 2: Bausch Health (BHC) - Bausch Health operates across multiple therapeutic areas, with its eye health business under Bausch + Lomb Corporation, and reported fourth-quarter 2025 results that missed earnings estimates but exceeded revenue expectations [9]. - The Salix business segment, which includes GI products, is a significant revenue contributor, with Xifaxan being the top revenue generator [11]. - Bausch Health expects 2026 revenues to be between $10.625 billion and $10.875 billion, with $5.375 billion to $5.475 billion coming from Bausch + Lomb [10][14]. - The company faced a setback with the failure of the RED-C clinical program, which did not meet its primary endpoint [15]. - Bausch Health's high levels of debt and generic competition in the market are ongoing concerns [16]. Group 3: Comparative Analysis - The Zacks Consensus Estimate for Ironwood's 2026 sales suggests a year-over-year increase of approximately 50.5%, while Bausch Health's estimate indicates a 4.2% increase [17][19]. - In the past six months, Ironwood's shares have surged by 291.5%, contrasting with a 21% decline in Bausch Health's shares [22]. - Ironwood's shares trade at a price-to-sales (P/S) ratio of 2.42, significantly higher than Bausch Health's 0.22, indicating a more expensive valuation for Ironwood [23]. - Ironwood is rated as a Zacks Rank 1 (Strong Buy), while Bausch Health holds a Zacks Rank 3 (Hold), suggesting a more favorable investment outlook for Ironwood [26]. - Despite Bausch Health's diversified operations, Ironwood's growth momentum and potential for long-term profitability position it as the better investment choice [28].

Group 1 - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare industries, highlighting key trends and catalysts that influence market valuations [1] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group, which caters to both novice and experienced investors [1] - The investing group provides insights such as buy and sell ratings, product sales forecasts for major pharmaceutical companies, integrated financial statements, discounted cash flow analysis, and market-specific analyses [1]

Core Insights - Bausch Health Companies Inc. (BHC) reported mixed results for Q4 2025, with adjusted EPS of $1.08 missing estimates but total revenues of $2.8 billion exceeding expectations, leading to a decline in share price during after-hours trading [1][6]. Financial Performance - Adjusted EPS of $3.73 for 2025 missed the Zacks Consensus Estimate of $3.90 and decreased from $3.75 in 2024 [11]. - Total revenues for 2025 were $10.3 billion, up 7% from 2024, surpassing the Zacks Consensus Estimate of $10.17 billion [11]. - Q4 total revenues increased by 9% year over year, reaching $2.8 billion, beating the Zacks Consensus Estimate of $2.7 billion [1][6]. Segment Performance - Bausch Health segment revenues were $1.4 billion, up 9% year over year, with Salix revenues at $693 million, also up 9% [3][4]. - Xifaxan, a key product in the Salix division, generated $607 million in sales, a 10% increase year over year [4]. - International revenues totaled $306 million, up 10% year over year, driven by growth in EMEA markets [7]. - Bausch + Lomb revenues reached $1.4 billion, up 10% year over year, with growth across vision care, surgical, and pharmaceuticals [10]. Guidance and Future Outlook - BHC expects 2026 revenues to be between $10.625 billion and $10.875 billion, above the consensus estimate of $10.49 billion [15]. - Excluding Bausch + Lomb, revenues are projected to be between $5.250 billion and $5.400 billion, while Bausch + Lomb revenues are expected to be between $5.375 billion and $5.475 billion [15]. Pipeline Developments - BHC announced the failure of the late-stage RED-C clinical program, which did not meet its primary endpoint despite the compound being safe [12][13]. - The company received Breakthrough Therapy Designation for larsucosterol for treating Alcohol-Associated Hepatitis [13]. - The Clear and Brilliant Touch program for skin rejuvenation is advancing with multiple international approvals [14]. Strategic Moves - BHC recently acquired Shibo's full-service aesthetics distribution business in China, enhancing its geographic footprint and access to a growing customer base [17]. - The company continues to face significant debt, with total obligations amounting to $20.2 billion as of December 31, 2025 [18].

Core Insights - Bausch Health Companies Inc. (BHC) experienced a 1% increase in stock price following the release of its third-quarter results last October 2025, but the fourth-quarter results fell short of expectations, with both revenue and revenue guidance disappointing [1] Group 1: Company Performance - The fourth-quarter bottom line for Bausch Health missed expectations, indicating potential challenges in meeting market forecasts [1] - The company’s revenue for Q4 did not meet analyst expectations, which may impact investor sentiment and future stock performance [1] Group 2: Analyst Background - Chris Lau, an individual investor and economist with 30 years of experience, covers life science, technology, and dividend-growth income stocks, providing insights into undervalued stocks and dividend-income recommendations [1]

Core Insights - Bausch Health's OraPharma celebrates the 25th anniversary of ARESTIN® (minocycline HCl) Microspheres, the only FDA-approved locally applied antibiotic for periodontal disease treatment [1] - ARESTIN is used in conjunction with scaling and root planing (SRP) to reduce pocket depth in adult patients with periodontitis, supported by over two decades of clinical experience [1] - The company emphasizes its commitment to periodontal care and innovation, aiming to improve access to treatment options in areas with unmet needs, including recent expansions into Canada and Puerto Rico [1] Product Overview - ARESTIN® (minocycline HCl) Microspheres, 1 mg, is specifically designed for adult periodontitis treatment and is part of a comprehensive oral health program [1] - The product delivers antibiotic therapy directly into the periodontal pocket using microspheres that gradually release the antibiotic [1] Market Context - Periodontal disease affects over one billion people globally, highlighting the significant need for effective treatment options [1] - The company aims to deepen collaboration with the dental community to enhance non-surgical periodontal treatment for appropriate patients [1]

Core Insights - Bausch Health reported revenue of $2.8 billion for the quarter ended December 2025, reflecting a year-over-year increase of 9.3% and exceeding the Zacks Consensus Estimate of $2.7 billion by 3.38% [1] - The company's EPS was $1.08, down from $1.15 in the same quarter last year, resulting in an EPS surprise of -10.5% compared to the consensus estimate of $1.21 [1] Revenue Breakdown - Total Bausch + Lomb revenues reached $1.41 billion, surpassing the average estimate of $1.37 billion by analysts, marking a year-over-year increase of 9.8% [4] - Revenues from Diversified Products were $255 million, exceeding the estimated $233.84 million, with an 11.8% increase year-over-year [4] - Bausch + Lomb's Vision Care segment generated $778 million, closely matching the average estimate of $778.13 million, reflecting a 7.6% year-over-year growth [4] - Surgical revenues amounted to $249 million, above the average estimate of $239.46 million, indicating a 7.8% increase year-over-year [4] - Total revenues excluding Bausch + Lomb were $1.39 billion, exceeding the $1.33 billion estimate, with an 8.8% year-over-year growth [4] - International revenues were reported at $306 million, surpassing the average estimate of $280.41 million, representing a 9.7% year-over-year increase [4] - Solta Medical revenues were $137 million, slightly below the average estimate of $143.46 million, showing a year-over-year decline of 0.7% [4] - Salix revenues reached $693 million, exceeding the estimated $669.92 million, with a year-over-year increase of 9.3% [4] - Bausch + Lomb Pharmaceuticals generated $378 million, surpassing the average estimate of $353.78 million, reflecting a significant year-over-year growth of 16% [4] Stock Performance - Bausch shares have returned -11.8% over the past month, compared to a -1.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

分组1 - Bausch Health reported quarterly earnings of $1.08 per share, missing the Zacks Consensus Estimate of $1.21 per share, and showing a decrease from $1.15 per share a year ago, resulting in an earnings surprise of -10.50% [1] - The company posted revenues of $2.8 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 3.38%, and an increase from $2.56 billion year-over-year [2] - Bausch has surpassed consensus revenue estimates three times over the last four quarters, while it has only surpassed consensus EPS estimates once in the same period [2] 分组2 - The stock has underperformed the market, losing about 13.8% since the beginning of the year, compared to the S&P 500's zero return [3] - The current consensus EPS estimate for the coming quarter is $0.82 on revenues of $2.43 billion, and for the current fiscal year, it is $4.07 on revenues of $10.49 billion [7] - The Medical - Generic Drugs industry, to which Bausch belongs, is currently in the bottom 20% of the Zacks Industry Rank, indicating potential challenges for stock performance [8]